**Introduction**

Pre-clinical studies have been performed by the TSA for the treatment of systemic malignancies and small animal models of peritoneal spread of cancer. As such, favorable results for both high systemic exposure to p.o. AVB-001 demonstrates tumor eradication in multiple tumor models.

**Results**

**Ovarian cancer model: AVB-001 completely eradicates tumor**
- **AVB-001 results in complete tumor suppression vs IP rIL-2 injection.**

**AVB-001 increases local cytotoxic T cell proliferation in IP fluid of mice with 10B6 tumors**

**LOCOcyte™ achieves tumor eradication in multiple tumor models**

**AVB-001 demonstrates dose-dependent IL-2 concentration in IP fluid of mice.**

**AVB-001 results well tolerated in NHP: no signs of local or systemic toxicities**

**Conclusions**

Local and systemic delivery of LOCOcyte™ harnesses both innate and adaptive immunity.

- Allogeneic cells engineered to produce native cytokines with higher T-cell proliferation potency than recombinant or engineered cytokines.
- Sustained IL-2 production with high concentration in IP cavity.
- **AVB-001 tumor adjacent delivery initiates local and systemic immune response with low systemic exposure to IL-2.**
- AVB-001 and AVB-002 monotherapy eradicates multiple tumor types in mice.
- **AVB-001 and AVB-002 modulate innate and adaptive immune responses.**
- **AVB-001 well tolerated in NHP and has a favorable safety/toxicity profile.**
- FHM clinical trial in ovarian cancer patients with AVB-001 to be ongoing (NCT05538624).